A practical reference on Angiotensin IV analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
=== Tendon treatment === Several studies have shown a correlation between the administration of bone growth factors and the amelioration of the tendon-to-bone healing. The focus of these studies was primarily on the anterior cruciate ligament (ACL) located in the knee, due to the high number of injuries sustained by athletes. The University of Dammam, King Fahd Hospital in Saudi Arabia was able to show that the addition of SHMSP bone growth factor via powder facilitated the process of tendon-graft healing in rabbits. Comparison of this SHMSP test group to the control group illustrated a higher level of formation and organization within the knee. The Hospital for Special Surgery in New York conducted a similar study, in which a collagen sponge containing bone protein was implanted in the ACL of rabbits. In this case, the bone protein isolated from bovine femurs contained several bone morphogenetic proteins, which are part of an important signaling system that aides in the structure of bones. As with the application of SHMSP, the inclusion of bone protein in the collagen sponge was seen to improve the healing process, when compared to control groups with the sponge alone or no sponge. In a separate study also implemented by the Hospital for Special Surgery as well as the University of California, treatment of the anterior cruciate ligament utilized the recombinant human bone morphogenic protein rhBMP-2 in two phases.
In recent years, the federal government conducted purges and prosecutions of police forces in Nuevo Laredo, Michoacán, Baja California, and Mexico City. The anti-cartel operations begun by President Calderón in December 2006 include ballistic checks of police weapons in places where there is concern that police are also working for the cartels. In June 2007, President Calderón purged 284 federal police commanders from all 31 states and the Federal District. Under the 'Cleanup Operation' performed in 2008, several agents and high-ranking officials have been arrested and charged with selling information or protection to drug cartels; some high-profile arrests were: Victor Gerardo Garay Cadena, (chief of the Federal Police), Noé Ramírez Mandujano (ex-chief of the Organized Crime Division (SEIDO)), José Luis Santiago Vasconcelos (ex-chief of SEIDO), and Ricardo Gutiérrez Vargas who is the ex-director of Mexico's Interpol office. In January 2009, Rodolfo de la Guardia García, ex-director of Mexico's Interpol office, was arrested. Julio César Godoy Toscano, who was elected in July 2009 to the lower house of Congress, was charged with being a top-ranking member of La Familia Michoacana. He is now a fugitive. In May 2010, an NPR report collected allegations from dozens of sources, including U.S. and Mexican media, Mexican police officials, politicians, academics, and others, that Sinaloa Cartel had infiltrated and corrupted the Mexican federal government and the Mexican military by bribery and other means.
For the above reasons, the demand for in-situ analysis is increasing. In-situ means analyzing monazite grains in their original host rocks without separation (refer to in situ) such that the texture and zonation pattern are kept intact in order to reveal a more comprehensive geological history of the host rock. Direct sampling techniques, high spatial resolution and precision are required for in-situ analysis. With technological advancement, more and more measurement tools such as laser ablation inductively coupled plasma mass spectrometry (LA-ICPMS) and laser microprobe mass spectrometer (LMMS) are capable of such analysis.
== Pharmacodynamics == Etoxadrol is a non-competitive NMDA receptor antagonist. It binds with high affinity to the PCP binding site on the NMDA receptor (Ki = 107 nM, determined by the displacement of radiolabeled TCP). Normally, the inactivated NMDA receptor possesses a magnesium (Mg2+) block in the channel, blocking the passage of cations.
Sources: en.wikipedia.org
The final pile consisted of 771,000 pounds of graphite, 80,590 pounds of uranium oxide, and 12,400 pounds of uranium metal, with ten cadmium control rods. Neutron intensity was measured with a boron trifluoride counter, with the control rods removed, after the end of each shift. On 2 Dec. 1942, with k approaching 1.0, Fermi had all but one of the control rod removed, and gradually removed the last one. The neutron counter clicks increased, as did the pen recorder, when Fermi announced "The pile has gone critical." They had achieved a k of 1.006, which meant neutron intensity doubled every two minutes, in addition to breeding plutonium.
The first Lower Saxon parliament or Landtag met on 9 December 1946. It was not elected; rather it was established by the British Occupation Administration (a so-called "appointed parliament"). That same day the parliament elected the Social Democrat, Hinrich Wilhelm Kopf, the former Hanoverian president (Regierungspräsident) as their first minister-president. Kopf led a five-party coalition, whose basic task was to rebuild a state afflicted by the war's rigours. Kopf's cabinet had to organise an improvement of food supplies and the reconstruction of the cities and towns destroyed by Allied air raids during the war years. Hinrich Wilhelm Kopf remained – interrupted by the time in office of Heinrich Hellwege (1955–1959) – as the head of government in Lower Saxony until 1961. The greatest problem facing the first state government in the immediate post-war years was the challenge of integrating hundreds of thousands of refugees from Germany's former territories in the east (such as Silesia and East Prussia), which had been annexed by Poland and the Soviet Union. Lower Saxony was at the western end of the direct escape route from East Prussia and had the longest border with the Soviet Zone. On 3 October 1950 Lower Saxony took over the sponsorship of the very large number of refugees from Silesia. In 1950 there was still a shortage of 730,000 homes according to official figures.
=== Not marketed === ACT-335827 – selective OX1 antagonist Almorexant (ACT-078573) – dual OX1 and OX2 antagonist – half-life 13–19 hours – development of the drug was abandoned in January 2011 EMPA – selective OX2 antagonist Filorexant (MK-6096) – dual OX1 and OX2 antagonist – half-life 3–6 hours – development was discontinued in 2015 GSK-649868 (SB-649868) – dual OX1 and OX2 antagonist – was in development for potential use in sleep disorders JNJ-10397049 – selective OX2 antagonist RTIOX-276 – selective OX1 antagonist SB-334867 – first non-peptide selective OX1 antagonist – has been shown to produce sedative and anorectic effects in animals SB-408124 – selective OX1 antagonist TCS-OX2-29 – first non-peptide selective OX2 antagonist
Caffeine has been found to increase striatal dopamine in animal models, as well as inhibit the inhibitory effect of adenosine receptors on dopamine receptors, however the implications for humans are unknown. Unlike most stimulants, caffeine has no addictive potential. Caffeine does not appear to be a reinforcing stimulus, and some degree of aversion may actually occur, per a study on drug abuse liability published in a NIDA research monograph that described a group preferring placebo over caffeine. In large telephone surveys only 11% reported dependence symptoms. However, when people were tested in labs, only half of those who claim dependence actually experienced it, casting doubt on caffeine's ability to produce dependence and putting societal pressures in the spotlight. Coffee consumption is associated with a lower overall risk of cancer. This is primarily due to a decrease in the risks of hepatocellular and endometrial cancer, but it may also have a modest effect on colorectal cancer. There does not appear to be a significant protective effect against other types of cancers, and heavy coffee consumption may increase the risk of bladder cancer. A protective effect of caffeine against Alzheimer's disease is possible, but the evidence is inconclusive. Moderate coffee consumption may decrease the risk of cardiovascular disease, and it may somewhat reduce the risk of type 2 diabetes. Drinking 1–3 cups of coffee per day does not affect the risk of hypertension compared to drinking little or no coffee.
Many macromolecules are synthetic polymers (plastics, synthetic fibers, and synthetic rubber). Polyethylene is produced on a particularly large scale such that ethylenes are the primary product in the chemical industry. Examples or different types of synthetic macromolecules include:
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.